| HOME >> BIOLOGY >> TECHNOLOGY |
specific products is available by calling the company or visiting
the Investor Relations Web site at http://ir.schering-plough.com.
SCHERING-PLOUGH CORPORATION
Reconciliation of Non-U.S. GAAP Financial Measures
Adjusted net sales, defined as net sales plus an assumed 50 percent of
global cholesterol joint venture net sales.
Three months ended December 31
(Dollars in millions) (unaudited)
2007 2006 %
Net sales, as reported a/ $3,724 $2,650 41%
50 percent of cholesterol
joint venture net sales b/ 722 541 33%
Adjusted net sales b/ $4,446 $3,191 39%
Twelve months ended December 31
(Dollars in millions) (unaudited)
2007 2006 %
Net sales, as reported a/ $12,690 $10,594 20%
50 percent of cholesterol
joint venture net sales b/ 2,559 1,915 34%
Adjusted net sales $15,249 $12,509 22%
a/ Net sales for the three and twelve months ended December 31, 2007, both
include $626 million recorded as a result of the Organon BioSciences
acquisition on November 19, 2007 through year-end.
b/ Total net sales of the cholesterol joint venture for the three months
ended December 31, 2007 and 2006 were $1.4 billion and $1.1 billion,
respectively. Total net sales of the cholesterol joint venture for the
twelve months ended December 31, 2007 and 2006 were $5.1 billion and
$3.8 bil
'/>"/>
| SOURCE Schering-Plough Corporation Copyright©2008 PR Newswire. All rights reserved |